Literature DB >> 11463525

Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.

E Gradelski1, L Valera, B Kolek, D Bonner, J Fung-Tomc.   

Abstract

The primary bactericidal classes used therapeutically as single agents, are the quinolones and the cell-wall active agents. In this study, their rates of killing were compared. The des-fluoro(6) quinolone BMS-284756 (T-3811ME), fluoroquinolones (trovafloxacin, levofloxacin) and cell wall-active agents (beta-lactams, vancomycin) were evaluated against Enterobacteriaceae, Staphylococcus aureus, streptococci, and Enterococcus faecalis. Time-kill analysis was done at 10x the MIC, using Mueller-Hinton broth (supplemented with 7% lysed horse blood for Streptococcus pneumoniae and the viridans streptococci), or Brain Heart Infusion broth for beta-haemolytic streptococci. Using a 3-log(10) decrease in viable count as an index of bactericidal activity, BMS-284756 and the fluoroquinolones killed Enterobacteriaceae rapidly, requiring < 2 h versus > or =6 h for beta-lactams. The staphylococcal cell counts generally decreased more rapidly with quinolone exposure, compared with those treated with vancomycin or the beta-lactams. The antimicrobial agents killed streptococci and enterococci more slowly, requiring > 6 h to decrease the viable count by 99.9%. In summary, BMS-284756 killing rates are similar to those of recent fluoroquinolones and are bacterial group-dependent. Overall, the quinolones are more rapidly bactericidal than vancomycin and the beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463525     DOI: 10.1016/s0924-8579(01)00343-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Authors:  Kim L Credito; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  The Advantage of Bactericidal Drugs in the Treatment of Infection.

Authors:  Jeffrey Alder; Barry Eisenstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

3.  Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  Philip Chung; Patrick J McNamara; Jeffrey J Campion; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa.

Authors:  Meher Rizvi; Junaid Ahmad; Fatima Khan; Indu Shukla; Abida Malik; Hiba Sami
Journal:  Australas Med J       Date:  2015-01-31

5.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Protection of Salmonella by ampicillin-resistant Escherichia coli in the presence of otherwise lethal drug concentrations.

Authors:  Michael H Perlin; Denise R Clark; Courtney McKenzie; Himati Patel; Nikki Jackson; Cecile Kormanik; Cayse Powell; Alexander Bajorek; David A Myers; Lee A Dugatkin; Ronald M Atlas
Journal:  Proc Biol Sci       Date:  2009-08-05       Impact factor: 5.349

7.  Population Density Modulates Drug Inhibition and Gives Rise to Potential Bistability of Treatment Outcomes for Bacterial Infections.

Authors:  Jason Karslake; Jeff Maltas; Peter Brumm; Kevin B Wood
Journal:  PLoS Comput Biol       Date:  2016-10-20       Impact factor: 4.475

8.  Aqueous extract of Hibiscus sabdariffa inhibits pedestal induction by enteropathogenic E. coli and promotes bacterial filamentation in vitro.

Authors:  Reda Mohamed-Salem; Carmina Rodríguez Fernández; Elvira Nieto-Pelegrín; Beatriz Conde-Valentín; Angel Rumbero; Narcisa Martinez-Quiles
Journal:  PLoS One       Date:  2019-03-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.